An Intracellular Enzyme Drug via Endocytosis: Olipudase Alfa (Xenpozyme)

In August 2022, olipudase alfa (Xenpozyme), a hydrolytic lysosomal sphingomyelin-specific enzyme indicated for non–CNS manifestations of acid sphingomyelinase deficiency (ASMD), was approved in the US and Europe.

This Premium deep dive into Xenpozyme includes:

  • the industry context,
  • the clinical data,
  • the target rationale,
  • the mechanism of action,
  • and the drug’s origins.

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more:


Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

Newsletter

Join Subscribers from